Company news

Avalo Therapeutics, Inc. news in 2026

Avalo Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Updates

November 5, 2026

Avalo Therapeutics to Participate in Upcoming Investor Conferences

November 2, 2026

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

September 29, 2026

Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress

September 23, 2026

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

August 6, 2026

Avalo Therapeutics to Participate in the BTIG Biotechnology Conference

July 22, 2026

Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum

July 7, 2026

Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes

June 26, 2026

Avalo Therapeutics Appoints Ron Philip to Board of Directors

June 23, 2026

Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody

June 16, 2026

Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

May 22, 2026

Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

May 13, 2026

Avalo Therapeutics Announces Pricing of $375 Million Public Offering

May 5, 2026

Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

May 5, 2026

Avalo Therapeutics Purchases Optional Milestone Buyout

April 28, 2026

Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates

March 22, 2026

Avalo Therapeutics to Participate in Upcoming Investor Conferences

February 4, 2026

Decks in 2026